Report of Foreign Issuer (6-k)
12 Dezembro 2017 - 9:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE
SECURITIES EXCHANGE ACT OF 1934
For the month of December 2017
Commission File Number: 001-36073
ENZYMOTEC
LTD.
(Translation of registrant’s name
into English)
Sagi 2000 Industrial Area
P.O. Box 6
Migdal Ha’Emeq 2310001, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F
x
Form 40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
o
EXPLANATORY NOTE
On December 11, 2017, Enzymotec Ltd.
(“Enzymotec” or the “Company”) held an annual and extraordinary general meeting of shareholders (the
“Meeting”). At the Meeting, the Company’s shareholders voted on three proposals, as described in the proxy
statement for the Meeting (the “Proxy Statement”) that was distributed by the Company to its shareholders and was
attached as Exhibit 99.1 to the Company’s Report of Foreign Private Issuer on Form 6-K (“Form 6-K”),
furnished to the Securities and Exchange Commission on November 17, 2017.
At the Meeting, shareholders of the Company
approved all proposals on the agenda that were presented to the shareholders by the requisite majorities under Israeli law.
The voting results
for the proposals presented at the Meeting, based on the presence in person or by proxy of holders of 18,648,992 (79.6%) of
our outstanding ordinary shares on the record date of November 13, 2017, are described below.
|
|
Proposal 1:
|
To
approve the acquisition of Enzymotec by Frutarom Ltd. ("Frutarom"), including the approval of: (i) the Agreement and Plan of
Merger, dated as of October 28, 2017 (as it may be amended from time to time, the “Merger Agreement”), by and
among Enzymotec, Frutarom, and Frutarom Tech Ltd., an Israeli company and a wholly-owned subsidiary of Frutarom
(“Merger Sub”); (ii) the merger of Merger Sub with and into Enzymotec (the “Merger”) on the terms and
subject to the conditions set forth in the Merger Agreement and in accordance with Sections 314-327 of the Israeli Companies
Law, 5759-1999, following which Merger Sub will cease to exist as a separate legal entity and Enzymotec will become a
wholly-owned subsidiary of Frutarom; (iii) the consideration to be received by the shareholders of Enzymotec in the Merger,
consisting of $11.90 per share in cash, without interest and less any applicable withholding taxes, for each ordinary share
of Enzymotec owned immediately prior to the effective time of the Merger; and (iv) all other transactions and arrangements
contemplated by the Merger Agreement, including, without limitation, the purchase by Enzymotec of a run-off directors’
and officers’ liability insurance policy for a period of seven years following the effective time of the merger (the
“Merger Proposal”).
|
Ordinary Majority:
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|
18,615,784
|
11,100
|
2,162
|
19,946
|
|
99.9%
|
0.01%
|
|
|
Special Majority (which excludes
ordinary shares voted by Merger Sub, Frutarom or any person or entity holding at least 25% of the means of control of either Merger
Sub or Frutarom, or any person or entity acting on behalf of either Merger Sub or Frutarom or any person or entity described in
the previous clause, or any family member of, or entity controlled by, any of the foregoing):
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|
13,777,141
|
11,100
|
2,162
|
19,946
|
|
99.9%
|
0.01%
|
|
|
|
|
Proposal 2(a):
|
To re-elect Holger Liepmann as a class I director of the Company, to serve until the Company’s annual general meeting of shareholders in 2020 and until his successor is duly elected and qualified, or until his earlier resignation, replacement or removal.
|
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|
15,425,583
|
3,202,151
|
3,162
|
18,096
|
|
82.8%
|
17.2%
|
|
|
|
|
Proposal 3:
|
To approve the reappointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Limited, as the Company’s independent, external auditors for the year ending December 31, 2017 and until the next annual general meeting of shareholders, and to authorize the Company’s board of directors (the “board of directors”) (with power of delegation to its audit committee) to set the fees to be paid to such auditors.
|
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|
17,688,131
|
11,625
|
949,236
|
0
|
|
99.9%
|
0.01%
|
|
|
Prior to the Meeting, Frutarom informed
the Company that it was withdrawing the nomination of its three nominees—Amos Anatot, Alon Shmuel Granot and Ari Rosenthal—for election by the Company’s shareholders to serve as Class I directors of the Company pursuant to Proposals 2(b), 2(c)
and 2(d), respectively, on the agenda for the Meeting. As noted in the Proxy Statement, the Company’s nominating and governance
committee had recommended, and the board of directors had approved, the nomination of the foregoing individuals as requested by
Frutarom pursuant to Frutarom’s rights under the Merger Agreement. As a result of Frutarom’s withdrawal request, each
of Proposals 2(b), 2(c) and 2(d) was removed from the agenda, and was not voted upon, at the Meeting.
As noted in the Proxy Statement, Proposals
2(a) and 3 relate to the function of the Meeting as the Company’s 2017 annual meeting of shareholders, and will be relevant
to the Company’s current shareholders only until the consummation of the Merger (assuming that it is consummated), at which
time they will cease to hold ordinary shares of the Company.
A copy of the press release announcing
the approval of the Merger Proposal at the Meeting is attached to this Form 6-K as Exhibit 99.1.
This
Form 6-K is hereby incorporated by reference into the Company’s registration statements on Form S-8, SEC file numbers 333-216734,
333-202839 and 333-193118, filed with the Securities and Exchange Commission on March 16, 2017, March 18, 2015 and December 30,
2013, respectively.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
ENZYMOTEC LTD.
|
|
Date: December 12, 2017
|
By:
|
/s/ Dror Israel
|
|
|
|
Name: Dror Israel
Title: Chief Financial Officer
|
Exhibit Index
ENZYMOTEC LTD. (NASDAQ:ENZY)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
ENZYMOTEC LTD. (NASDAQ:ENZY)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
